Our experience working with VirTus was terrific. They were easy to interact with, collaborative, and provided helpful advice and information at every turn throughout the clinical trial.
BRENTON SCOTT, PRESIDENT AND COO, PULMOTECT, INC.
Pulmotect, Inc.
Virtus Respiratory Research Ltd were contracted by Pulmotect, Inc. to test a novel Toll-like receptor (TLR) agonist as a treatment for exacerbations of chronic respiratory disorders ClinicalTrials.gov Identifier: NCT03794557.
This Phase 2a study utilised current smokers with normal lung function yet that experience some symptoms of COPD (GOLD Stage 0 COPD volunteers). The treatment and placebo were delivered twice during the study, first dose on day -1 and another on day 2, post rhinovirus-A16 challenge on day 0. All dosing is delivered by nebuliser. Volunteers were followed for 6 weeks. Primary efficacy endpoints were lower respiratory symptom score, and secondary or exploratory endpoints included upper respiratory symptom score, virus load, number of infected subjects and inflammatory cells and biomarkers in blood, sputum and nasal lavage.
The study commenced recruitment in January 2019 and is currently ongoing. Recruitment has utilised print, social media and a commercial recruiting agency. Results are expected to be realised in the second half of 2020. All results will be published on clinical trials.gov.
Pulmotect, Inc.
Virtus Respiratory Research Ltd were contracted by Pulmotect, Inc. to test a novel Toll-like receptor (TLR) agonist as a treatment for exacerbations of chronic respiratory disorders ClinicalTrials.gov Identifier: NCT03794557.
This Phase 2a study utilised current smokers with normal lung function yet that experience some symptoms of COPD (GOLD Stage 0 COPD volunteers). The treatment and placebo were delivered twice during the study, first dose on day -1 and another on day 2, post rhinovirus-A16 challenge on day 0. All dosing is delivered by nebuliser. Volunteers were followed for 6 weeks. Primary efficacy endpoints were lower respiratory symptom score, and secondary or exploratory endpoints included upper respiratory symptom score, virus load, number of infected subjects and inflammatory cells and biomarkers in blood, sputum and nasal lavage.
The study commenced recruitment in January 2019 and is currently ongoing. Recruitment has utilised print, social media and a commercial recruiting agency. Results are expected to be realised in the second half of 2020. All results will be published on clinical trials.gov.
Our experience working with VirTus was terrific. They were easy to interact with, collaborative, and provided helpful advice and information at every turn throughout the clinical trial.
BRENTON SCOTT, PRESIDENT AND COO, PULMOTECT, INC.
